title: Hypersensitivity to alkylation treatment of primary fibroblasts from patients with therapy-related myeloid neoplasms.
authors.forename: Julia
authors.initials: J
authors.lastname: Rankl
authors.forename: Karin
authors.initials: K
authors.lastname: Flicker
authors.forename: Angelika
authors.initials: A
authors.lastname: Valentin
authors.forename: Michael
authors.initials: M
authors.lastname: Horn
authors.forename: Selman
authors.initials: S
authors.lastname: Uranüs
authors.forename: Andrea
authors.initials: A
authors.lastname: Groselj-Strele
authors.forename: Werner
authors.initials: W
authors.lastname: Emberger
authors.forename: Heinz
authors.initials: H
authors.lastname: Sill
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use; D001706:Biopsy; D019046:Bone Marrow Neoplasms / Q000139:chemically induced* / Q000473:pathology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004249:DNA Damage / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000473:pathology*; D061251:Primary Cell Culture; D012867:Skin / Q000473:pathology
chemical_list: D018906:Antineoplastic Agents, Alkylating